![]() | |
Names | |
---|---|
Preferred IUPAC name
N-(2-Aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide | |
Identifiers | |
3D model (
JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
KEGG | |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C23H20N6O | |
Molar mass | 396.454 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia. [1] [2] [3]
One clinical trial (for refractory follicular lymphoma) was temporarily put on hold due to cardiac problems but resumed recruiting in 2009. [4]
In 2010 favourable results were announced from the phase II trial for Hodgkin's lymphoma. [5]
MGCD0103 has also been used as a research reagent where blockage of members of the HDAC-family of histone deacetylases is required. [6]
It works by inhibiting mainly histone deacetylase 1 ( HDAC1), but also HDAC2, HDAC3, and HDAC11. [7]
![]() | |
Names | |
---|---|
Preferred IUPAC name
N-(2-Aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide | |
Identifiers | |
3D model (
JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
KEGG | |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C23H20N6O | |
Molar mass | 396.454 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia. [1] [2] [3]
One clinical trial (for refractory follicular lymphoma) was temporarily put on hold due to cardiac problems but resumed recruiting in 2009. [4]
In 2010 favourable results were announced from the phase II trial for Hodgkin's lymphoma. [5]
MGCD0103 has also been used as a research reagent where blockage of members of the HDAC-family of histone deacetylases is required. [6]
It works by inhibiting mainly histone deacetylase 1 ( HDAC1), but also HDAC2, HDAC3, and HDAC11. [7]